Evaluation of Breast Disorders - Gynecology and Obstetrics - Merck

Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) —dedicated to using leading-edge science to save and improve lives around the world. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge.

Frontiers Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer

Fibrocystic breast changes - Wikipedia

Nipple Discharge: Causes, Symptoms, and Treatment

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry, Breast Cancer Research

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis, BMC Cancer

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer - Modern Pathology

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer - Modern Pathology

Frontiers Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer

Breast cancer Nature Reviews Disease Primers

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy